Identification and Management of AD Uncontrolled With Topical Therapies in Children

No matches

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: QatarChange country/region

Identification and Management of AD Uncontrolled With Topical Therapies in Children

Related resources

Skin Barrier Dysfunction and Type 2 Inflammation in Atopic Dermatitis

What is Early Intervention in AD?

Disease Modification in AD

Systemic Inflammation in AD – Beyond the Skin

Dysbiosis, Skin Infections, and Itch

Skin Barrier Dysfunction in AD

Early Intervention and the Potential for Disease Modification in Children With AD

Emerging Data on Advanced Systemic Treatments for Children With AD

Within and Beyond the Skin: New Perspectives on the Role of Type 2 Inflammation in AD

Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?

Itch: Neuroimmune Axis in Chronic Pruritic Skin Diseases

Neuroiflammation and Neurogenic Itch in Prurigo Nodularis

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

A brief overview of the pathophysiology of PN

Most Burdensome Symptoms Rated by PN Patients

Current systemic therapies have been shown to induce remission in a subset of AD patients

Can advanced systemic therapies modify pathomechanisms in AD?

Type 2 Inflammation at the Neuroimmune Axis in PN and CSU

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

Characteristics of Chronic Itch in PN and CSU

Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU

Expert Interview: Inflammatory Cell Infiltrate and Type 2 Inflammation in PN and CSU

Expert Interview: The Importance of Explaining Disease Pathogenesis to PN and CSU Patients

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

Is Pediatric AD Linked to Other Allergic Diseases?

Itch and Inflammation in Two Distinct Diseases: PN and CSU

Long-term Impacts of AD and the Potential Benefit of Early Intervention

New Data on the Systemic (Multi-Organ) Burden of AD in Children and the Need for Early Intervention

Practical Considerations in Older Patients with AD

Scratching May Increase Neurogenic Inflammation in PN and CSU

The Benefits of Early Intervention in AD: More Than Skin Deep

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

The Cumulative Disease Burden of AD in Adult Patients

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis

ADVENT On Air | First-hand Experience: Practical Insights On the Diagnosis and Assessment of Atopic Dermatitis of the Hands and Feet

ADVENT On Air | Exploring PN as a Distinct and Unique Disease

What do we mean by disease control in AD?

Barrier disruption in AD and the development of environmental and food allergies

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

What Could Remission Mean in AD?

The Risks of Associated Systemic and Atopic Comorbidities with AD

Factors Associated With Development of Atopic Comorbidities in AD

Can Early Intervention Shape the Course of Atopic Dermatitis?

Association of Younger Age of Onset With Persistence of AD

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?

Explore the Global Burden of Pediatric AD (PEDISTAD)

Type 2 Inflammation in AD Manifestations in Skin and Body

Learning objectives

About this expert

Perla Lansang